Cancer Prevention and Control CIRB Meeting Agenda

January 27, 2022

I. Continuing Review

S1614, A Phase III Randomized Trial of Prophylactic Antiviral Therapy in Patients with Current or Past Hepatitis B Virus (HBV) Infection Receiving Anti-Cancer Therapy for Solid Tumors (Protocol Version Date 06/03/21)

II. Continuing Review

A191901, Optimizing Endocrine Therapy Through Motivational Interviewing and Text Interventions (Protocol Version Date 11/09/20)

III. Continuing Review

NRG-CC003, Randomized Phase II/III Trial of Prophylactic Cranial Irradiation with Or without Hippocampal Avoidance for Small Cell Lung Cancer (Protocol Version Date 04/13/21)

IV. Continuing Review

URCC-16092, Phase II Study of Low-Dose Ibuprofen for Cognitive Problems in Patients with Cancer (Protocol Version Date 04/22/20)

V. Continuing Review

UWI2015-05-01, Phase Ib 9cUAB30 in Early Stage Breast Cancer to Evaluate Biologic Effect (Protocol Version Date 04/14/21)

VI. Continuing Review

WF-1805CD, Implementation and Effectiveness Trial of HN-STAR (Protocol Version Date 10/04/21)
VII. New Study - Initial Review


VIII. New Study - Initial Review

INT21-05-01, Phase IIB Clinical Trial of the Multitargeted Recombinant Adenovirus 5 (CEA/MUC1/Brachyury) Vaccine (TRI-AD5) and IL-15 Superagonist N-803 in Lynch Syndrome (Protocol Version Date 11/30/21)

IX. Amendment ReReview

A231701CD, Increasing Socioeconomically Disadvantaged Patients’ Engagement in Breast Cancer Surgery Decision-Making Through a Shared Decision Making Intervention (Protocol Version Date 01/05/22)

X. Amendment

UWI2015-05-01, Phase Ib 9cUAB30 in Early Stage Breast Cancer to Evaluate Biologic Effect (Protocol Version Date 12/17/21)